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Objective: To investigate the prevalence of the different types of hepatitis C virus (HCV) in a population of chronic 
HCV carriers using the Murex HCV serotyping l-6 assay. 
Methods: All serum samples from these patients had a positive nested PCR HCV reaction. The sera were submitted 
to ELISA, modified, for the identification of antibodies against HCV serotypes 1, 2, 3, 4, 5 and 6 (Murex HCV 
serotyping l-6 assay). 
Results: The viral serotype was identified in 166 (75.8%) of the 219 patients, 108 (65.11%) males and 58 (34.9%) 
females, Patient age ranged from 12 to 73 years, with a mean of 41.1 years. The form of acquisition of the disease 
most frequently reported was blood transfusion. The results showed a predominance of type 1 (70.0%) followed by 
type 3 (22.3%) and type 2 (4.2%). 
Conclusion: Samples presenting low and very close optical density readings may lead to discrepant diagnoses 
concerning HCV serotypes and should be confirmed by genotyping. The serotyping can be useful in clinical practice 
and can be of help in establishing the prognosis of the disease, also favoring epidemiologic studies independently of 
the technology required for genotyping tests. 
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INTRODUCTION 
The agent responsible for most cases of parenterally 
transmitted hepatitis non A non B (HNANB), i.e. hepa- 
titis C virus (HCV), was discovered by Choo et al in 
1989.’ HCV is considered to be a flavivirus with an 
envelope and a diameter of 30-38 nm. The virus has a 
single-stranded RNA genome, with positive polarity and 
approximately 10 000 nucleotides, which presents the 3’- 
NC and 5’-NC regions (non-coding) at its extremities. 
A long open reading frame containing almost the entire 
genome codes for a polyprotein of approximately 3010- 
3011 amino acids. These amino acids are subdivided into 
nine proteins in the following order: nucleocapsid or core 
(C) and two viral envelope glycoproteins, El and E2/NSl, 
which contain the structural domain of the genome, 
and NS2, NS3, NS4a, NS4b, NS5a and NSSb, which are 
nonstructural domains.2 
Several studies have recently reported that HCV 
exhibits considerable heterogeneity in its molecular 
structure, probably as a result of small replication 
errors and of spontaneous mutations occurring in the 
genome.3-4 
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Analysis of the nucleic acid sequences of HCV 
isolated in different parts of the world has demonstrated 
up to 30% diversity and, on the basis of this variability, 
the following four categories have been established: 
types, subtypes, isolates, and quasi-species. A unified 
system of HCV genotype classification has been pro- 
posed in order to standardize the various nomenclatures 
described in different research centers in the world. 
The sequences of the NS5 region of HCV have been 
compared in variants from different parts of the world, 
and it has been established that a similarity of less 
than 72% with some known genomic sequence of HCV 
demonstrates the existence of a new viral type. Among 
those considered to belong to the same subgroup (sub- 
type), the degree of similarity ranges from 75% to 
86% (mean: 80%). Thus, six types (1, 2, 3, 4, 5, 6) 
presenting 2-3 subtypes (a, b, c) are currently considered 
for some of these genotypes. New HCV variants 
have been reported in Vietnam, Thailand, Burma and 
Indonesia, and were first classified as genotypes 7,8,9, 
10 and 11. However, complementary analyses have 
suggested that types 7, 8, 9 and 11 should be classified 
within genotype 6a, and type 10 as a subtype of type 
3a.4-6 
The clinical-pathologic importance of each geno- 
type is currently the subject of intense investigation. 
Several studies have discussed the different types of 
prognosis for hepatitis C and the response to treatment 
with interferon-alpha, theoretically related to the 
different types of HCV7,8 
Different methods are available for the identifi- 
cation and differentiation of genotypes, each with 
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advantages and disadvantages. Several aspects should be 
taken into account, such as specificity and sensitivity, 
cost, handling time, and facilities available. In addition 
to genotyping techniques, a new alternative for the 
identification of HCV types is serotyping, i.e. the 
identification of type-specific antibodies against the NS4 
regions and also of the HCV core, without the need 
for the presence of the viral particle or for molecular 
biology techniques.“.“’ 
There are some important geographic variations in 
the prevalence of genotypes. Types la, lb, 2a, 2b and 3a 
are those most commonly found in Brazil, western 
Europe and the USA, whereas lb, 2a and 2b are more 
frequently found in Japan and Taiwan. Type 3 is more 
prevalent in India, Bangladesh and other parts of Asia, 
type 4 in the Middle East, type 5 in South Africa, and 
type 6 in Hong Kong and Macao.?.“,” 
Competitive ELISA (Murex HCV serotyping l-6 
assay), which uses synthetic peptides based on the NS4 
region of the HCV genome, identifies the six HCV types 
described thus far. The great advantage of this serologic 
method over molecular biology methods is the ability 
to process a large number of samples on a single day, 
as well as the possibility of execution in routine labora- 
tories not equipped with the facilities needed for 
molecular biology techniques.12 
The objective of the present study was to investigate 
the prevalence of the different types of HCV in a 
population of chronic HCV carriers using the Murex 
HCV serotyping 1-6 assay. 
MATERIALS AND METHODS 
Patients 
We evaluated 219 patients seen at the Hepatitis 
Outpatient Clinic of the University Hospital, University 
of Sao Paulo, from 1990 to 1997. All patients had a 
clinical and laboratory diagnosis (second-generation 
ELISA) and a positive PCR HCV for hepatitis C. Data 
concerning age, sex and mode of transmission were 
obtained from the medical records of the patients. 
Serum samples 
Blood was collected from the patients by vacuum 
venipuncture using a dry lo-mL tube. The serum was 
separated, centrifuged, aliquoted and stored at -20°C 
until the time of use. Some of the samples were used 
after thawing for PCR HCV. 
Nested PCR 
We used the external primers NCR2 and PTCl and 
the internal primers PTC3 and NCR4. Results were 
considered to be positive for PCR HCV according to the 
proposed protocol.‘3-‘5 
Serotyping analysis 
Serotypes were determined by the Murex HCV sero- 
typing l-6 assay. This assay is used for the detection of 
type-specific antibodies against NS4-derived epitopes, 
presented as branched peptides in a microliter 96-well 
format. Serotyping was performed according to the 
manufacturer’s instructions. The results were scored as 
specific serotype, multiple serotypes, no type-specific 
antibodies, or non-reactive, according to the interpre- 
tation criteria established.lh 
Statistical analysis 
Since the samples with serotypes 1, 2 and 3 are 
independent and random, the three groups were com- 
pared for age by analysis of variance (F statistic). The 
presumed modes of HCV acquisition were compared 
among the three groups by the x2 test. It was not possible 
to compare certain variables, because the expected fre- 
quencies were lower than 1. In the final analysis, we 
considered a history of blood transfusion and hemophilia 
in the same group, as well as unknown forms of trans- 
mission and patients whose medical records did not 
contain the information (unknown). 
The patients were divided into three groups for 
statistical analysis of epidemiologic data, i.e. serotype 1, 
serotype 2 and serotype 3 groups. 
The level of significance was set at a=0.05 in all 
tests. 
RESULTS 
Among the 219 patients included in the study, HCV type 
was diagnosed by serotyping in 166, corresponding to 
75.8% sensitivity for the Murex HCV serotyping l-6 
assay. The results showed a predominance of type 1 
(70%) followed by type 3 (22.3%) and type 2 (4.2%). 
Infection with two or more types was detected in 3.6% 
of the samples (Table 1). 
Of the 166 patients, 108 (65.1%) were male and 58 
(34.9%) female. Patient age ranged from 12 to 73 years 
(mean: 41.1 years). 
The serotype 1 group consisted of 74 males (60.7%) 
and 48 females (39.3%) ranging in age from 12 to 73 
years (mean: 40.6 years). The serotype 2 group consisted 
Table 1. Distribution of HCV serotypes among the 166 samples 
diagnosed 
Serotype No. of patients % 
1 116 70.0 
2 7 4.2 
3 37 22.3 
1+2 1 0.6 
1+3 2 1.2 
1+4 2 1.2 
1+2+5 1 0.6 
Total 166 100.0 
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Table 2. Patient distribution by presumed form of HCV acquisition 
Mode of acquisitionlantecedent 
Transfusion 
Intravenous drug use 
Hemophilia 
Tattoo 
Acupuncture 
Sexual 
Health professional 
Needle accident 
Unknown 
Not found in the medical record 
Total 
Total 
no. (%) 
52 (31.33) 
18 (10.84) 
1 (0.60) 
8 (4.82) 
1 (0.60) 
6 (3.61) 
2 (1.20) 
(1.81) 
6: (36.75) 
14 (8.43) 
166 (100) 
TVpe 1 
no. (%j 
38 (31.15) 
12 (9.84) 
1 (0.82) 
5 (4.10) 
1 (0.82) 
4 (3.28) 
1 (0.82) 
4: (3(::2; 
12 (9.84) 
122 (100) 
TVpe 2 Type 3 
no. (%) no. (%) 
3 (33.33) 12 (30.77) 
0 (0.00) 6 (15.38) 
0 (0.00) 0 (0.00) 
1 (11.11) 2 (5.13) 
0 (0.00) 0 (0.00) 
1 (11.11) 1 (2.56) 
0 (0.00) 1 (2.56) 
(0.00) 
; (22.22) 
(0.00) 
1: (41.03) 
2 (22.22) 1 (2.56) 
9 (100) 39 (100) 
Some patients reported more than one antecedent. 
of six males (66.7%) and three females (33.3%) ranging 
in age from 3.5 to 62 years (mean: 47.6 years), and the 
serotype 3 group consisted of 28 males (71.8%) and 11 
females (28.2%) ranging in age from 26 to 67 years 
(mean: 41.1 years) (age: 1;=1.64 and p=O.2). 
Overall distribution by presumed form of acquisition 
of the disease revealed blood transfusion as the most 
frequent antecedent, being reported by 38/122 patients 
(31.2%) in the serotype 1 group, by 3/9 patients (33.3%) 
in the serotype 2 group, and by 12/39 patients (30.8%) 
in the serotype 3 group (Table 2). Age and history of 
blood transfusion did not differ significantly among the 
three serotypes as risk factors (x2=0.04 and p=O.98). It 
was not possible to test the distribution of other selected 
factors according to diagnosed serotype because the 
expected frequencies were lower than 1. 
It was not possible to determine the HCV serotype 
for 42 patients (19.2%) possibly due to antibody levels 
below the detection limits of the test being present in 
these samples. 
Of the 219 patients included in the study, 197 
were evaluated by Western blot (Abbott-Murex, 
Dartford, UK) for an individualized diagnosis of the 
presence of anti-NS4 HCV antibodies. Of the 42 
samples that could not be typed by serotyping, 36 were 
evaluated and 23 (63.9%) showed negative results for 
the presence of these antibodies (P<0.001).17 
Seven samples were sequenced and the results are 
compared in Table 3. 
Table 3. Serotypes detected and respective sequencing 
Serotype Sequencing a 
1 lb 
;,b3 
lb 
lb 
2 and 2.5 2b 
3 3a 
3 and 6 3a 
6 lb 
a(Centro de lmunologia e lmunogenbtica S/C Ltda - SBo Paulo, Brazil). 
bserotyping was repeated three times. 
DISCUSSION 
Mapping of the epitopes of protein NS4 of the HCV 
genome revealed two important antigenic regions 
(1691-1708 and 1710-1728) which proved to be highly 
variable among genotypes 1,2,3,4,5 and 6 and whose 
type-specific antibodies could be detected. Type-specific 
peptides corresponding to these two regions were 
synthesized and later used for indirect ELISA, in which 
a complete peptide line for the six HCV types was 
projected and included in the assay (a total of 21 
peptides).12 
The sensitivity projected in our experiment may 
perhaps have been impaired by the fact that the reaction 
steps were not fully automated, with a consequent 
increase in total reaction time and probably impaired 
quality of the washings. The immunologic competence of 
the patients studied should also be considered, since 
we did not exclude those who were being treated with 
interferon-alpha or any other type of medication, or even 
those with associated diseases. 
Comparative data reported in the literature for 
genotyping and serotyping suggest that the sensitivity 
of serotyping methods is significantly lower than that 
of molecular biology techniques. The sensitivity of 
serotyping tests can also be limited by the immuno- 
competence of the host.i6 
The results obtained revealed a predominance of 
type 1, in agreement with the literature surveyed. It 
should be emphasized the studies citing Brazilian samples 
used genotyping techniques, showing that the results of 
this new method for the diagnosis of HCV types agree 
with the results reported here.3J8 
The epidemiologic parameters evaluated were age, 
sex and mode of HCV transmission. For six patients 
who mentioned probable sexual transmission, no other 
antecedents that would explain acquisition of the 
disease were found, except for the sexual partner, who 
presented the same HCV serotype. No significant differ- 
ences between types 1,2 and 3 of HCV were detected 
with respect to these parameters. In the USA, Mahaney 
et all9 and Watson et a120 reported no significant differ- 
ences between HCV genotypes and patient age or sex 
distribution in their studies. 
In the present study, in relation to the samples 
for which it was not possible to determine the HCV 
serotype, there were frequently extremely low optical 
density (OD) readings for all HCV types tested, in- 
cluding the controls. Thus, we may assume that the 
volume of anti-NS4 or HCV type-specific antibodies 
may have been very low during that phase of infection, 
impairing the performance of this serologic test.” 
Van Doorn et a12’ reported that the immunocom- 
petence of the infected host can also interfere with the 
sensitivity of the assay. 
The mixed infection results may be explained by the 
serologic detection of previous infections with different 
HCV types. However, the presence of cross-reactions 
should not be ruled out and would probably explain 
most of these results, and therefore these diagnoses, 
especially when OD readings showed values >2.5 in 
control wells or when the values of negative reference 
wells persisted at ~4.0. This may represent the presence 
of excess antibodies in the sample and consequently 
positive results for more than one HCV type.16.21-2” 
Serotype 6 was not confirmed for any of the samples 
tested. Type 6a appears to be one of the types most 
confined to a determined geographic region and is found 
only in the Hong Kong, Macao and Vietnam regions.h,24 
Serotype 5 was confirmed for only one patient. 
Serotype 4 was present in two patients. The possibility of 
cross-reaction could be considered; also, the origin of 
this patient and his form of HCV acquisition should be 
investigated. 
Campiotto et al ** genotyped 705 Brazilian samples 
and detected a 0.9% prevalence of types 4 and 5. All of 
them were located in the State of Sao Paulo. 
We had the opportunity of sequencing seven samples, 
which were selected in order to confirm serotypes 1,2 
and 3, to clarify some mixed infections, and to investigate 
a serotype 6 sample. Thus, the high percentage of dis- 
cordant results was expected. The sample of serotype 2, 
retested three times, presented results for the lb geno- 
type during sequencing. For the serotyping tests, the 
OD readings were very low, although they fulfilled the 
requirements of the test, which were followed rigorously. 
Perhaps these OD values indicate a small volume of 
type-specific antibodies and the possibility of cross- 
reactions or nonspecific reactions. 
Serotyping was based on epitopes of the NS4 region 
and on the sequencing of the 5’NC region of the HCV 
genome. The hypothesis of discordance as a function of 
the different HCV regions explored should also be con- 
sidered. 
The discussion about the sensitivity of the Murex 
test is not really relevant, as this test is not an HCV 
diagnostic test. This is a subtyping test applied to 
samples already shown by other more sensitive tests to 
be infected with HCV, so it is not expected to have the 
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levels of sensitivity that PCR or second/third-generation 
ELISA tests have to diagnose HCV infection. 
Despite the limitations pointed out in the present 
report and in view of the results obtained, which were 
compatible with those of other studies based on 
molecular biology for the investigation of HCV types, 
we conclude that serotyping can be useful in clinical 
practice and can be of help in establishing the prognosis 
of the disease, also favoring epidemiologic studies of 
regions or countries independently of the technology 
required for genotyping tests. 
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